NeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic Research
|
SUNNYVALE, Calif., Dec. 3, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced that it has entered a license agreement with Boston Children's Hospital. As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced neurons. The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions. "We are pleased to license this advantageous technology that was originated from Dr. Thomas Südhof's laboratory at Stanford University," said Mustafa Sahin, MD, PhD, director of the Translational Neuroscience Center and Human Neuron Core at Boston Children's and professor of neurology at Harvard Medical School. "We hope this technology will enable us and other researchers to create a tool that closely resembles human biology in vitro and will become an important part of our effort to improve human health." "NeuCyte has the exclusive rights to Stanford's original neuronal induction technology and has further developed it to incorporate into our proprietary in vitro drug discovery platforms," said Jonathan Davila, PhD, Co-founder and CEO of NeuCyte. "We are happy to get the technology into the hands of Boston Children's Hospital where it can be further used for academic research. We also welcome discussions with other organizations who are interested in this technology." About NeuCyte, Inc. Contact:
SOURCE NeuCyte, Inc. |
View original content: